The Impact of Bdnf Gene Deficiency to the Memory Impairment and Brain Pathology of APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Brain-derived neurotrophic factor (BDNF) importantly regulates learning and memory and supports the survival of injured neurons. Reduced BDNF levels have been detected in the brains of Alzheimer's disease (AD) patients but the exact role of BDNF in the pathophysiology of the disorder remains obscure. We have recently shown that reduced signaling of BDNF receptor TrkB aggravates memory impairment in APPswe/PS1dE9 (APdE9) mice, a model of AD. The present study examined the influence of Bdnf gene deficiency (heterozygous knockout) on spatial learning, spontaneous exploratory activity and motor coordination/balance in middle-aged male and female APdE9 mice. We also studied brain BDNF protein levels in APdE9 mice in different ages showing progressive amyloid pathology. Both APdE9 and Bdnf mutations impaired spatial learning in males and showed a similar trend in females. Importantly, the effect was additive, so that double mutant mice performed the worst. However, APdE9 and Bdnf mutations influenced spontaneous locomotion in contrasting ways, such that locomotor hyperactivity observed in APdE9 mice was normalized by Bdnf deficiency. Obesity associated with Bdnf deficiency did not account for the reduced hyperactivity in double mutant mice. Bdnf deficiency did not alter amyloid plaque formation in APdE9 mice. Before plaque formation (3 months), BDNF protein levels where either reduced (female) or unaltered (male) in the APdE9 mouse cortex. Unexpectedly, this was followed by an age-dependent increase in mature BDNF protein. Bdnf mRNA and phospho-TrkB levels remained unaltered in the cortical tissue samples of middle-aged APdE9 mice. Immunohistological studies revealed increased BDNF immunoreactivity around amyloid plaques indicating that the plaques may sequester BDNF protein and prevent it from activating TrkB. If similar BDNF accumulation happens in human AD brains, it would suggest that functional BDNF levels in the AD brains are even lower than reported, which could partially contribute to learning and memory problems of AD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 1×
“in hippocampus [36].”
Neurotrophins as synaptic modulators
Poo, M.-M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35049004 · Cited by 1,775 · cited 1×
“synaptogenesis and neuronal plasticity and maintenance in several brain areas and neuronal subsystems has been well characterized [6,10,11].”
BackgroundNEUROTROPHINS AND SYNAPTIC PLASTICITY
McAllister, A. K., Katz, L. C., & Lo, D. C. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.295 · Cited by 1,337 · cited 1×
“synaptogenesis and neuronal plasticity and maintenance in several brain areas and neuronal subsystems has been well characterized [6,10,11].”
BackgroundMice lacking brain-derived neurotrophic factor develop with sensory deficits
Ernfors, P., Lee, K.-F., & Jaenisch, R. (1994) · Nature · doi:10.1038/368147a0 · Cited by 1,067 · cited 2×
“The development of Bdnf heterozygote knockout mice (C57BL6/J background) have been described previously by Ernfors et al [31] (obtained from Jackson Laboratory).”
MethodA phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 1×
“Indeed, NGF delivery into the brain ameliorates memory impairment associated with old age [8] and amyloid-b infusion [26] in rats, and most importantly, clinical AD [27].”
BackgroundNagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 1×
“Furthermore, viral transduction or direct infusion of BDNF protein in the entorhinal cortex has been shown to reverse neuronal atrophy and synapse loss in an AD mouse model as well as in aged rats and primates [28].”
BackgroundPotential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867 · cited 1×
“Previous studies indicating abnormal neurotrophin signaling in AD together with the known ability of neurotrophins to support survival of their target neurons after injury has led to a suggestion that neurotrophins could prevent or delay neuronal and synaptic loss seen in neurodegenerative disorders, including AD [25].”
BackgroundBDNF regulates eating behavior and locomotor activity in mice
Kernie, S. G., Liebl, D. J., & Parada, L. F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.6.1290 · Cited by 806 · cited 2×
“As described in earlier studies [43], we found significantly increased body weight of Bdnf mice when compared to wildtype mice in both genders (males: F1,61 = 15.”
BackgroundCharacterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.017 · Cited by 744 · cited 1×
“Consequently, amyloid plaques gradually develop in the cortex and hippocampus of APdE9 mice starting at 4 months of age [1], which is followed by memory impairment 4–8 months later [2,3].”
BackgroundPeng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691
Hock, C., Heese, K., Hulette, C., Rosenberg, C., & Otten, U. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.846 · Cited by 523 · cited 1×
“Moreover, reduced levels of BDNF mRNA and protein (pro and mature) have been detected in AD patients and in some animal models of AD [14–23].”
BackgroundRantamäki, T., Hendolin, P., Kankaanpää, A., Mijatovic, J., Piepponen, P., Domenici, E., Chao, M. V., Männistö, P. T., & Castrén, E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301345 · Cited by 305
Self-citationRegional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimerʼs disease
Narisawa-Saito, M., Wakabayashi, K., Tsuji, S., Takahashi, H., & Nawa, H. (1996) · NeuroReport · doi:10.1097/00001756-199611250-00024 · Cited by 226 · cited 1×
“Moreover, reduced levels of BDNF mRNA and protein (pro and mature) have been detected in AD patients and in some animal models of AD [14–23].”
BackgroundTong, L., Thornton, P. L., Balazs, R., & Cotman, C. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010450200 · Cited by 206 · cited 1×
“Most of these data are favoring overall reduced BDNF synthesis in AD [17,21,22,47], that is thought to arise from direct effects of amyloid-b (Ab) on Bdnf synthesis [48].”
BackgroundBurbach, G. J., Hellweg, R., Haas, C. A., Del Turco, D., Deicke, U., Abramowski, D., Jucker, M., Staufenbiel, M., & Deller, T. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5599-03.2004 · Cited by 132 · cited 5×
“Furthermore, in agreement with a previous report [44], significant BDNF immunoreactivity was predominantly seen around amyloid plaques in APdE9 mice.”
BackgroundMethodResultInfluentialRantamäki, T., Vesa, L., Antila, H., Di Lieto, A., Tammela, P., Schmitt, A., Lesch, K.-P., Rios, M., & Castrén, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020567 · Cited by 124 · cited 1×
“The generation and validation of this antibody has been characterized in previous publications [38–40].”
MethodSelf-citationSzapacs, M. E., Numis, A. L., & Andrews, A. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.04.010 · Cited by 49
Cited by
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
Azman, K. F., & Zakaria, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126827 · Cited by 221
Isoflurane produces antidepressant effects and induces TrkB signaling in rodents
Antila, H., Ryazantseva, M., Popova, D., Sipilä, P., Guirado, R., Kohtala, S., Yalcin, I., Lindholm, J., Vesa, L., Sato, V., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08166-9 · Cited by 84
Self-citationCohen, S. M., Suutari, B., He, X., Wang, Y., Sanchez, S., Tirko, N. N., Mandelberg, N. J., Mullins, C., Zhou, G., Wang, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04705-8 · Cited by 67
New insights on brain‐derived neurotrophic factor epigenetics: from depression to memory extinction
Poon, C. H., Heng, B. C., & Lim, L. W. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14458 · Cited by 40
Metadata
- Authors
- Rantamäki, T., Kemppainen, S., Autio, H., Stavén, S., Koivisto, H., Kojima, M., Antila, H., Miettinen, P. O., Kärkkäinen, E., Karpova, N., Vesa, L., Lindemann, L., Hoener, M. C., Tanila, H., & Castrén, E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-07-03
- Volume
- 8
- Issue
- 7
- Pages
- e68722
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2038075714
- Cited by
- 51
- References
- 17
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.